FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242644170> ?p ?o ?g. }

• W4242644170 endingPage "e667" @default.
• W4242644170 startingPage "e667" @default.
• W4242644170 abstract "INTRODUCTION AND OBJECTIVE: Although dapoxetine is the only oral pharmacological agent approved for the treatment of premature ejaculation (PE), and is very effective, the discontinuation rate is high. We assessed the discontinuation rate in patients with PE, and the reasons for discontinuation, in real-world practice. METHODS: A total of 182 consecutive patients were enrolled. The type of PE, the self-estimated intravaginal ejaculation latency time (IELT), and medical history were evaluated in all patients, who also completed the International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) questionnaire. Visits were scheduled 1, 3, 6, 12, and 24 months after initiation of therapy; we checked treatment status and the reasons for discontinuation in those who did in fact discontinue. We compared the relationships of discontinuation rates with various parameters and the time to discontinuation after treatment commencement. RESULTS: Of all patients, 9.9% continued treatment to 2 years. The cumulative discontinuation rates at 1, 3, 6, 12, and 24 months were 26.4%, 61.6%, 79.1%, 87.3%, and 90.1%, respectively. 79.1% of all patients discontinued treatment within 6 months. After 12 months, however, the discontinuation rate fell sharply. The reasons for discontinuation were cost (29.9%), disappointment that PE was not curable and that dapoxetine was required every time sexual intercourse was contemplated (25%), side effects (11.6%), perceived poor efficacy (9.8%), a search for other treatment options (5.5%), and unknown (18.3%). Patients with acquired PE (compared to lifelong PE), with IELT >2 min prior to treatment, on PDE-5 inhibitors, and with IIEF-EF scores <26 tended to discontinue early and thus exhibited high drop-out rates. CONCLUSIONS: The treatment discontinuation rate of dapoxetine was very high. The main reasons for discontinuation were the cost and disappointment that treatment was required every time adequate sexual function was required. Source of Funding: None" @default.
• W4242644170 created "2022-05-12" @default.
• W4242644170 creator A5009239854 @default.
• W4242644170 creator A5017519850 @default.
• W4242644170 creator A5020195123 @default.
• W4242644170 creator A5035529595 @default.
• W4242644170 creator A5042010713 @default.
• W4242644170 creator A5057348291 @default.
• W4242644170 creator A5062771321 @default.
• W4242644170 date "2020-04-01" @default.
• W4242644170 modified "2023-10-18" @default.
• W4242644170 title "MP45-07 DISCONTINUATION OF DAPOXETINE TREATMENT IN PATIENTS WITH PREMATURE EJACULATION" @default.
• W4242644170 doi "https://doi.org/10.1097/ju.0000000000000900.07" @default.
• W4242644170 hasPublicationYear "2020" @default.
• W4242644170 type Work @default.
• W4242644170 citedByCount "0" @default.
• W4242644170 crossrefType "journal-article" @default.
• W4242644170 hasAuthorship W4242644170A5009239854 @default.
• W4242644170 hasAuthorship W4242644170A5017519850 @default.
• W4242644170 hasAuthorship W4242644170A5020195123 @default.
• W4242644170 hasAuthorship W4242644170A5035529595 @default.
• W4242644170 hasAuthorship W4242644170A5042010713 @default.
• W4242644170 hasAuthorship W4242644170A5057348291 @default.
• W4242644170 hasAuthorship W4242644170A5062771321 @default.
• W4242644170 hasConcept C11171543 @default.
• W4242644170 hasConcept C126322002 @default.
• W4242644170 hasConcept C15744967 @default.
• W4242644170 hasConcept C187212893 @default.
• W4242644170 hasConcept C2778715236 @default.
• W4242644170 hasConcept C2779892816 @default.
• W4242644170 hasConcept C2779929075 @default.
• W4242644170 hasConcept C2780202899 @default.
• W4242644170 hasConcept C2908647359 @default.
• W4242644170 hasConcept C71924100 @default.
• W4242644170 hasConcept C99454951 @default.
• W4242644170 hasConceptScore W4242644170C11171543 @default.
• W4242644170 hasConceptScore W4242644170C126322002 @default.
• W4242644170 hasConceptScore W4242644170C15744967 @default.
• W4242644170 hasConceptScore W4242644170C187212893 @default.
• W4242644170 hasConceptScore W4242644170C2778715236 @default.
• W4242644170 hasConceptScore W4242644170C2779892816 @default.
• W4242644170 hasConceptScore W4242644170C2779929075 @default.
• W4242644170 hasConceptScore W4242644170C2780202899 @default.
• W4242644170 hasConceptScore W4242644170C2908647359 @default.
• W4242644170 hasConceptScore W4242644170C71924100 @default.
• W4242644170 hasConceptScore W4242644170C99454951 @default.
• W4242644170 hasLocation W42426441701 @default.
• W4242644170 hasOpenAccess W4242644170 @default.
• W4242644170 hasPrimaryLocation W42426441701 @default.
• W4242644170 hasRelatedWork W173961128 @default.
• W4242644170 hasRelatedWork W2019667886 @default.
• W4242644170 hasRelatedWork W2066385285 @default.
• W4242644170 hasRelatedWork W2316327342 @default.
• W4242644170 hasRelatedWork W2393410614 @default.
• W4242644170 hasRelatedWork W2583913962 @default.
• W4242644170 hasRelatedWork W3097751339 @default.
• W4242644170 hasRelatedWork W4231375873 @default.
• W4242644170 hasRelatedWork W47313593 @default.
• W4242644170 hasRelatedWork W84177330 @default.
• W4242644170 hasVolume "203" @default.
• W4242644170 isParatext "false" @default.
• W4242644170 isRetracted "false" @default.
• W4242644170 workType "article" @default.